For patients with large benign colonic lesions, endoscopic submucosal dissection (ESD) is associated with reduced recurrence at six months compared with endoscopic mucosal resection (EMR), according ...
Compared to minimally invasive surgery, endoscopic submucosal dissection (ESD) represents an advanced, less-invasive endoscopic treatment for early gastrointestinal cancer. ESD has significant ...
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) ...
Effectiveness and safety of first-line atezolizumab in locally advanced or metastatic urothelial cancer: The IMFLAME study. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers ...
Endoscopic submucosal dissection (ESD) appeared effective for removing superficial gastric neoplasia and is therefore a viable option for patients in North America, a retrospective, multicenter study ...
The American Gastroenterological Association (AGA) has released a comprehensive clinical practice update on lifting agents for endoscopic surgery. Published in Clinical Gastroenterology and Hepatology ...
For permission requests, please contact NEJM Reprints at [email protected] Select the format you want to export the citation of this publication.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results